BIVI To Launch Oral Bordetella Vaccine

Posted: April 3, 2012, 6:00 p.m. EDT



Published:

Boehringer Ingelheim Vetmedica Inc. received U.S. Food and Drug Administration approval for an oral vaccine that aids in the protection against the primary pathogen of canine infectious respiratory disease in dogs.

The vaccine, called Bronchi-Shield Oral, is the first live, avirulent Bordetella bronchiseptica vaccine licensed to be administered orally to dogs, the St. Joseph, Mo.-based company said.

“Doctors told us they like intranasal vaccines because they provide optimal immune responses, but doctors and their patients dislike having these vaccines given in the nose,” said Arne Zislin, VMD, technical manager veterinarian for BIVI. “So we’ve developed an easy-to-administer oral vaccine that is mucosally absorbed.”

The vaccine proved to provide protection against B. bronchiseptica in a challenge study, according to Zislin.

Administration requires veterinarians to instill a 1.0 mL dose into the buccal cavity of healthy dogs eight weeks of age or older, and the company recommends annual revaccination.

B. bronchiseptica vaccines are considered noncore by the American Animal Hospital Association 2011 Vaccination Guidelines, but BIVI says many dogs are at risk of infection.

<HOME>

Edit Module
Edit ModuleShow Tags

Archive »Read More

WVC Hits Road Again for Vet Education

Western Veterinary Conference, after honoring numerous veterinarians in Las Vegas, will hold CE classes in two more cities.

Wound Care Company Oculus Launches Animal Unit

Three over-the-counter MicrocynAH products are released, and a veterinary formulation could be out soon.

Tuskegee Joins VMCAS Clearinghouse

Tuskegee and Tufts are the newest members of the centralized Veterinary Medical College Application Service.

Add your comment:
Edit Module
Edit ModuleEdit ModuleShow Tags Edit Module
Edit Module Edit Module
Edit ModuleShow Tags

Events


Show More...
Edit Module
Edit Module